Expression of Mcl-1 splicing variants in clear-cell renal cancer and their correlation with histopathological parameters and prognosis

Tumor Biology

Volumn 30, Issue 2, 2009, Pages 73-79

  Kempkensteffen, Carsten ^a   Hinz, Stefan ^a   Johannsen, Manfred ^a   Krause, Hans ^a   Magheli, Ahmed ^a   Christoph, Frank ^a   Köllermann, Jens ^b   Schrader, Mark ^a   Schostak, Martin ^a   Miller, Kurt ^a   Weikert, Steffen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Apoptosis; Mcl 1; mRNA; Prognosis; Renal cell carcinoma

Indexed keywords

PROTEIN MCL 1; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BCL 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CANCER TISSUE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; GENE EXPRESSION; GENETIC VARIABILITY; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RNA SPLICING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA SPLICING;

EID: 65449131246     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000215826     Document Type: Article

References (38)

1. Reed JC: Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17: 2941-2953.
2. Igney FH, Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-288.
3. Cory S, Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656.
4. Craig RW: MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002; 16: 444-454.
5. Warr MR, Shore GC: Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 2008; 8:138-147.
6. Bae J, Leo CP, Hsu SY, Hsueh AJ: MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapo-ptotic protein possessing only the BH3 domain. J Biol Chem 2000; 275:25255-25261.
7. Bingle CD, Craig RW, Swales BM, Singleton V, Zhou P, W hy te M K : E xon sk ippi ng in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J Biol Chem 2000; 275:22136-22146.
8. Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoy ne R, Berea n K, Reed JC: Immuno-histochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995; 146: 1309-1319.
9. Michels J, O'Neill JW, Dallman CL, Mouza-kiti A, Habens F, Brimmell M, Zhang KY, Craig RW, Marcusson EG, Johnson PW, Packham G: Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-me-diated cleavage. Oncogene 2004; 23:4818- 4827.
10. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M: Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100:194-199.
11. Cho-Vega JH, Rassidakis GZ, Admirand JH, Oyarzo M, Ramalingam P, Paraguya A, McDonnell TJ, Amin HM, Medeiros LJ: MCL-1 expression in B-cell non-Hodgkin's lympho-mas. Hum Pathol 2004; 35:1095-1100.
12. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Hersey P: Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod Pathol 2007; 20:416-426.
13. Song L, Coppola D, Livingston S, Cress D, Haura EB: Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 2005; 4:267-276.
14. SanoM, Nakanishi Y, Yagasaki H, Honma T, Oinuma T, Obana Y, Suzuki A, Nemoto N: Overexpression of anti-apoptotic Mcl-1 in testicular germ cell tumours. Histopathology 2005; 46: 532 - 539.
15. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, Boding-bauer M, Crevenna R, Monia BP, Peck-Radosavljevic M, Wacheck V: Mcl-1 overex-pression in hepatocellular carcinoma: a potential target for antisense therapy. J Hep-atol 20 06; 44: 151-157.
16. Miyamoto Y, Hosotani R, Wada M, Lee JU, Koshiba T, Fujimoto K, Tsuji S, Nakajima S, Doi R, Kato M, Shimada YImamura M: Im-munohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology 1999; 56:73-82.
17. Chung TK, Cheung TH, Lo WK, Yim SF, Yu MY, Krajewski S, Reed JC, Wong YF: Expression of apoptotic regulators and their significance in cervical cancer. Cancer Lett 2002; 180: 63-68.
18. Ding Q, He X, Xia W, Hsu JM, Chen CT, Li LY, Lee DF, Yang JY, Xie X, Liu JC, Hung MC: Myeloid cell leukemia-1 inversely correlates with glycogen synt hase ki nase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res 2007; 67: 4564-4571.
19. Kaufmann SH, Karp JE, Svingen PA, Kra-jewski S, Burke PJ, Gore SD, Reed JC: Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998; 91: 991-1000.
20. Khoury JD, Medeiros LJ, Rassidakis GZ, McDonnell TJ, Abruzzo LV, Lai R: Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol 2003; 199: 90-97.
21. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemore-sponses. Blood 1998; 91: 3379-3389.
22. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, Hills R, Ward R, Starc-zynski J, Austen B, Hooper L, Stankovic T, Fegan C: Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008;112:3807- 3817.
23. Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H, Harousseau JL, Amiot M, Bataille R: Mcl-1 is overexpressed in multiple myeloma and as-sociated with relapse and shorter survival. Leukemia 2005; 19:1248-1252.
24. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 1996; 335: 865- 875.
25. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A: Prognostic in-dicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163: 1090-1095;quiz 1295.
26. Phuoc NB, Ehara H, Gotoh T, Nakano M, Yo-koi S, Deguchi T, Hirose Y: Immunohisto-chemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma. Urolog y 20 07; 69: 843- 848.
27. Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF, Kirschnek S, Hartmann C, Fritsch RM, Gillissen B, Daniel PT, Hacker G: Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 2007; 26: 7038-7048.
28. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
29. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006; 12: 7271-7278.
30. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA: The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005; 24: 6861-6869.
31. Karge WH 3rd, Schaefer EJ, Ordovas JM: Quantification of mRNA by polymerase chain reaction (PCR) using an internal standard and a nonradioactive detection method. Methods Mol Biol 1998; 110:43-61.
32. Atzpodien J, Kirchner H, Hanninen EL, Deckert M, Fenner M, Poliwoda H: Interleu-kin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29(suppl 5):S6-S8.
33. Erovic BM, Pelzmann M, Grasl M, Pammer J, Kornek G, Brannath W, Selzer E, Thurnher D: Mcl-1, vascular endothelial growth factor-R2, and 14-3-3sigma expression might predict primary response against radiotherapy and chemotherapy in patients with lo-cally advanced squamous cell carcinomas of the head and neck. Clin Cancer Res 2005; 11: 8632-8636.
34. Itoi T, Yamana K, Bilim V, Takahashi K, To-mita F: Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer 2004; 90: 200-205.
35. Kempkensteffen C, Hinz S, Christoph F, Kollermann J, Krause H, Schrader M, Schostak M, Miller K, Weikert S: Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance. Int J Cancer 2007; 120: 1081-1086.
36. Jonasch E, Tannir NM: Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J 2008; 14: 315-319.
37. Lam JS, Belldegrun AS, Figlin RA: Adjuvant treatment for renal cell carcinoma. Expert Opin Pharmacother 2006; 7: 705-720.
38. Ravaud A, Wallerand H, Culine S, Bernhard JC, Fergelot P, Bensalah K, Patard JJ: Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 2008; 54:315-325.